PR-104: Difference between revisions

Latest revision as of 03:40, 13 February 2025

PR-104[edit]

PR-104 is a hypoxia-activated prodrug that is being investigated for its potential use in cancer therapy. It is designed to target hypoxic regions within tumors, which are areas with low oxygen levels that are often resistant to conventional therapies.

Mechanism of Action[edit]

PR-104 is a prodrug, meaning it is inactive until it is metabolized into its active form. Under hypoxic conditions, PR-104 is converted into PR-104H, a cytotoxic agent that can damage DNA and kill cancer cells. This conversion is facilitated by reductase enzymes that are more active in low-oxygen environments.

Clinical Development[edit]

PR-104 has been evaluated in several clinical trials to assess its safety and efficacy in treating various types of cancer, including leukemia and solid tumors. The drug is often studied in combination with other chemotherapeutic agents to enhance its therapeutic effects.

Hypoxia in Tumors[edit]

Hypoxia is a common feature of solid tumors due to their rapid growth and inadequate blood supply. Hypoxic tumor cells are often more aggressive and resistant to treatment, making them a significant target for novel therapies like PR-104.

Related pages[edit]

@@ Line 1: / Line 1: @@
-'''PR-104''' is a [[bioreductive prodrug]] designed to be activated in hypoxic conditions, a common feature of many types of solid [[tumors]]. It was developed by the [[University of Auckland]] and is currently being investigated for its potential use in [[cancer therapy]].
+== PR-104 ==
-== History ==
+[[File:PR-104_structure.svg|thumb|right|Chemical structure of PR-104]]
-PR-104 was first synthesized by researchers at the University of Auckland in [[New Zealand]]. The development of PR-104 was based on the concept of [[hypoxia (medical)|hypoxia]], a condition in which there is a decrease in the oxygen supply to a tissue. Hypoxia is a common feature of many types of solid tumors and is associated with resistance to conventional therapies.
+'''PR-104''' is a hypoxia-activated prodrug that is being investigated for its potential use in cancer therapy. It is designed to target hypoxic regions within tumors, which are areas with low oxygen levels that are often resistant to conventional therapies.
 == Mechanism of Action ==
-PR-104 is a bioreductive prodrug, which means it is converted into its active form in the body. The conversion of PR-104 to its active form is facilitated by [[enzyme|enzymes]] that are present in higher concentrations in hypoxic cells. The active form of PR-104 then interferes with the [[DNA]] of the cancer cells, preventing them from replicating and causing them to die.
-== Clinical Trials ==
+PR-104 is a prodrug, meaning it is inactive until it is metabolized into its active form. Under hypoxic conditions, PR-104 is converted into PR-104H, a cytotoxic agent that can damage DNA and kill cancer cells. This conversion is facilitated by reductase enzymes that are more active in low-oxygen environments.
-PR-104 has been tested in several [[clinical trial|clinical trials]] for various types of cancer, including [[leukemia]], [[non-small cell lung cancer]], and [[soft tissue sarcoma]]. The results of these trials have shown that PR-104 has potential as a treatment for these types of cancer, particularly in patients who have not responded to other treatments.
+== Clinical Development ==
+PR-104 has been evaluated in several [[clinical trials]] to assess its safety and efficacy in treating various types of cancer, including [[leukemia]] and [[solid tumors]]. The drug is often studied in combination with other chemotherapeutic agents to enhance its therapeutic effects.
+== Hypoxia in Tumors ==
+[[Hypoxia]] is a common feature of solid tumors due to their rapid growth and inadequate blood supply. Hypoxic tumor cells are often more aggressive and resistant to treatment, making them a significant target for novel therapies like PR-104.
+== Related pages ==
-== Future Research ==
+* [[Cancer therapy]]
-Future research on PR-104 will focus on further understanding its mechanism of action and determining the most effective way to use it in cancer therapy. This may involve combining PR-104 with other treatments or using it as a second-line treatment in patients who have not responded to other therapies.
+* [[Prodrug]]
+* [[Hypoxia]]
+* [[Chemotherapy]]
-[[Category:Drugs]]
+[[Category:Experimental cancer drugs]]
-[[Category:Cancer treatments]]
 [[Category:Prodrugs]]
-{{Pharma-stub}}